UPDATE - New Study Reveals Potential Treatment for Neurological Lyme Disease
April 19, 2024 12:45 ET
|
Bay Area Lyme Foundation
PORTOLA VALLEY, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, recently announced publication of a laboratory study...
New Study Reveals Potential Treatment for Neurological Lyme Disease
April 18, 2024 11:00 ET
|
Bay Area Lyme Foundation
PORTOLA VALLEY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, recently announced publication of a laboratory study showing...
OPTIZMO™ Releases 2023 Email Opt-Out Infographic
April 18, 2024 09:00 ET
|
OPTIZMO Technologies, LLC
The infographic presents unique insights and data from hundreds of millions of opt-out requests, focusing on timing, geographic location, and device usage.
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 18, 2024 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
Renewables and nascent low-carbon technologies most exposed to high interest rates
April 18, 2024 06:25 ET
|
Wood Mackenzie
NEWS RELEASE Renewables and nascent low-carbon technologies most exposed to high interest rates Policymakers should...
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
April 17, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
April 17, 2024 07:00 ET
|
atai Life Sciences
BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally.BPL-003 was shown to be safe and well-tolerated with a predictable...
Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics
April 17, 2024 03:00 ET
|
Sound Bioventures
Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford New funding enables Theolytics...
Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor
April 17, 2024 03:00 ET
|
Theolytics
Oxford, UK April 17th, 2024. Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, today announced it has successfully closed its latest financing round, raising a...
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
April 16, 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Names Ed Pershing as Chief Executive Officer and Dominic Rodrigues as President KNOXVILLE, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the...